Influence of Patient and Treatment Factors on Adherence to Adjuvant Endocrine Therapy in Breast Cancer
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
PURPOSE/OBJECTIVES: To comprehensively assess the patient and illness or treatment factors that may predict nonadherence to adjuvant endocrine therapy and to explore whether an interaction occurs between these factors in women with breast cancer. DESIGN: Repeated-measures design. SETTING: The Outpatient Services of the Women's Cancer Program at the University of Pittsburgh Cancer Institute and participants' homes. SAMPLE: 91 women with early-stage breast cancer who received endocrine therapy. METHODS: Adherence was assessed continuously for the first 18 months of endocrine therapy. Patient and illness or treatment factors were assessed at four time points (Time 1 to Time 4). Time 1 (baseline) was within two weeks prior to the initiation of endocrine therapy. Times 2-4 occurred at six-month intervals, as many as 18 months after Time 1. MAIN RESEARCH VARIABLES: Adherence, patient factors, and illness or treatment factors. FINDINGS: Adherence to endocrine therapy declined significantly during the first 18 months of treatment in women with breast cancer. The presence of negative mood and symptoms before starting treatment predicted nonadherence to endocrine therapy over time. Perceptions of financial hardship, symptoms, disease stage, and more complex medication regimens intensified the effect of negative mood on adherence over time. CONCLUSIONS: Women with breast cancer may be at risk for nonadherence to prescribed endocrine therapy if they experience depression or anxiety and symptoms prior to initiating therapy. IMPLICATIONS FOR NURSING: Oncology nurses should be alert to women with breast cancer who are depressed or anxious or who are experiencing symptoms. Management of negative mood and symptoms may result in better adherence.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Elevated anxiety predicts nonadherence to recommended therapies, [23][24][25] higher use and costs of medical care, [26][27][28] and possibly cancer recurrence.29”
From Management of Anxiety and Depression in Adult Survivors of Cancer: ASCO Guideline Update (2023) · cites this paper as [24]
Citations
Cites
Beck, A. T., Steer, R. A., & Brown, G. (2011) · PsycTESTS Dataset · doi:10.1037/t00742-000 · Cited by 7,535
Horne, R., Weinman, J., & Hankins, M. (1999) · Psychology & Health · doi:10.1080/08870449908407311 · Cited by 2,372 · cited 1×
“Perceived treatment efficacy was evaluated with the 10-item Beliefs About Medicines Questionnaire (BMQ)–specific subscale (Horne, Weinman, & Hankins, 1999).”
Measuring the Functional Components of Social Support
Cohen, S., Mermelstein, R., Kamarck, T., & Hoberman, H. M. (1985) · Social Support: Theory, Research and Applications · doi:10.1007/978-94-009-5115-0_5 · Cited by 2,296 · cited 2×
“Test-retest correlations were 0.87 for two days, 0.7 for six weeks, and 0.74 for six months (Cohen et al., 1985).”
InfluentialSelf-citationPatient adherence to treatment: three decades of research. A comprehensive review
Vermeire, E., Hearnshaw, H., Van Royen, P., & Denekens, J. (2001) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.2001.00363.x · Cited by 1,833 · cited 1×
“Although the potential negative impact of financial hardship related to disease management on nonadherence has been explored (Griffith, 1990; Morris & Schulz, 1992; Vermeire, Hearnshaw, Van Royen, & Denekens, 2001), little is known about the role of financial hardship on”
Tamoxifen in the Treatment of Breast Cancer
Osborne, C. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811263392207 · Cited by 1,320
Mor, V., Laliberte, L., Morris, J. N., & Wiemann, M. (1984) · Cancer · doi:10.1002/1097-0142(19840501)53:9<2002::aid-cncr2820530933>3.0.co;2-w · Cited by 1,067 · cited 1×
“Although the potential negative impact of financial hardship related to disease management on nonadherence has been explored (Griffith, 1990; Morris & Schulz, 1992; Vermeire, Hearnshaw, Van Royen, & Denekens, 2001), little is known about the role of financial hardship on”
Neuropsychological assessment.
Garb, H. N. (2004) · Studying the clinician: Judgment research and psychological assessment. · doi:10.1037/10299-006 · Cited by 876
Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer
Partridge, A. H., Wang, P. S., Winer, E. P., & Avorn, J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.07.071 · Cited by 676
Leukemia, E. I. C. M. (2013) · Blood · doi:10.1182/blood-2013-03-490003 · Cited by 592
Konecny, G., Pauletti, G., Pegram, M., Untch, M., Dandekar, S., Aguilar, Z., Wilson, C., Rong, H.-M., Bauerfeind, I., Felber, M., et al. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.2.142 · Cited by 588 · cited 1×
“About 80% of breast cancers express hormone receptors (Konecny et al., 2003).”
Patient adherence and persistence with oral anticancer treatment
Ruddy, K., Mayer, E., & Partridge, A. (2009) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20004 · Cited by 569 · cited 1×
“Electronic monitoring has been used in other clinical studies measuring adherence to oral anticancer therapies (Ruddy, Mayer, & Partridge, 2009).”
Adherence to Initial Adjuvant Anastrozole Therapy Among Women With Early-Stage Breast Cancer
Partridge, A. H., LaFountain, A., Mayer, E., Taylor, B. S., Winer, E., & Asnis-Alibozek, A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5451 · Cited by 482 · cited 3×
“As hypothesized by the authors, and similar to the results of other investigators (Partridge et al., 2008), adherence to endocrine therapy declined significantly during the first 18 months of therapy in women with breast cancer.”
BackgroundResultAdherence to pharmacologic therapy in patients with type 2 diabetes mellitus
Rubin, R. R. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.04.012 · Cited by 406 · cited 1×
“The COIN captures expenses stemming from indirect and out-of-pocket costs associated with cancer care throughout the previous month (Rubin, 2005).”
Sprinkle, S. D., Lurie, D., Insko, S. L., Atkinson, G., Jones, G. L., Logan, A. R., & Bissada, N. N. (2002) · Journal of Counseling Psychology · doi:10.1037/0022-0167.49.3.381 · Cited by 398 · cited 2×
“83) (Sprinkle et al., 2002; Stukenberg, Dura, & Kiecolt-Glaser, 1990) and the Revised Hamilton Rating Scale for Depression (0.”
InfluentialPatient compliance-an overview
Morris, L. S., & Schulz, R. M. (1992) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.1992.tb01306.x · Cited by 331 · cited 1×
“Although the potential negative impact of financial hardship related to disease management on nonadherence has been explored (Griffith, 1990; Morris & Schulz, 1992; Vermeire, Hearnshaw, Van Royen, & Denekens, 2001), little is known about the role of financial hardship on”
Adherence to tamoxifen over the five-year course
Lash, T. L., Fox, M. P., Westrup, J. L., Fink, A. K., & Silliman, R. A. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9193-0 · Cited by 320 · cited 7×
“Lash et al. (2006) found that women with breast cancer who were taking four or more medications when initiating tamoxifen were less likely to discontinue the drug; however, if women began taking additional medications after initiating tamoxifen, they were more likely to stop taking tamoxifen (Lash…”
InfluentialManaging Menopausal Symptoms in Breast Cancer Survivors: Results of a Randomized Controlled Trial
Ganz, P. A. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.13.1054 · Cited by 312 · cited 2×
“…treatment-related symptoms were assessed with the Breast Cancer Prevention Trial (BCPT) Symptom Checklist , a self-report measure of the degree to which women are bothered by 43 hormone therapy-and menopausal-related symptoms in the month prior (Ganz et al., 2000; Stanton, Bernaards, & Ganz, 2005).”
Owusu, C., Buist, D. S. M., Field, T. S., Lash, T. L., Thwin, S. S., Geiger, A. M., Quinn, V. P., Frost, F., Prout, M., Yood, M. U., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.1022 · Cited by 304 · cited 6×
“, 2004) were more likely to discontinue therapy; however, women who had breastconserving surgery (Owusu et al., 2008) and changed”
InfluentialAdjuvant Tamoxifen: Predictors of Use, Side Effects, and Discontinuation in Older Women
Demissie, S., Silliman, R. A., & Lash, T. L. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.322 · Cited by 300 · cited 7×
“Most investigators have found that disease-and treatment-related symptoms are associated with nonadherence to endocrine therapy in women with breast cancer (Demissie et al., 2001; Fink et al., 2004; Grunfeld et al., 2005; Kahn et al., 2007; Wickersham et al., 2013).”
InfluentialIntentional and non-intentional non-adherence to medication amongst breast cancer patients
Atkins, L., & Fallowfield, L. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.03.004 · Cited by 300 · cited 1×
“For example, the relationship between demographic characteristics, such as age and race, and nonadherence is not clear (Atkins & Fallowfield, 2006; Demissie et al., 2001; Kahn, Schneider, Malin, Adams, & Epstein, 2007; Murthy et al., 2002; Owusu et al., 2008; Sedjo & Devine, 2011; Partridge, Wang,…”
Fink, A. K., Gurwitz, J., Rakowski, W., Guadagnoli, E., & Silliman, R. A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.064 · Cited by 281 · cited 6×
“Most investigators have found that disease-and treatment-related symptoms are associated with nonadherence to endocrine therapy in women with breast cancer (Demissie et al., 2001; Fink et al., 2004; Grunfeld et al., 2005; Kahn et al., 2007; Wickersham et al., 2013).”
InfluentialAdherence to adjuvant endocrine therapy in postmenopausal women with breast cancer
Ziller, V., Kalder, M., Albert, U.-S., Holzhauer, W., Ziller, M., Wagner, U., & Hadji, P. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn646 · Cited by 263 · cited 2×
“Ziller et al. (2009) found no relationship between disease-and treatment-related symptoms and nonadherence; however, adherence was measured via self-report and symptoms were documented by medical record review.”
Adherence to endocrine therapy for breast cancer
Chlebowski, R. T., & Geller, M. L. (2006) · Oncology · doi:10.1159/000100444 · Cited by 251 · cited 1×
“Studies that examined the influence of patient and illness or treat-ment factors on nonadherence to endocrine therapy in women with breast cancer have produced conflicting results (Chlebowski & Geller, 2006; Owusu et al., 2008; Wickersham et al., 2013).”
Patient Centered Experiences in Breast Cancer: Predicting Long-Term Adherence to Tamoxifen Use
Kahn, K. L., Schneider, E. C., Malin, J. L., Adams, J. L., & Epstein, A. M. (2007) · Medical Care · doi:10.1097/01.mlr.0000257193.10760.7f · Cited by 245 · cited 4×
“Several studies stated that self-reported symptoms were related to nonadherence (Wickersham et al., 2013) and higher endocrine therapy discontinuation rates (Demissie et al., 2001; Fink et al., 2004; Grunfeld et al., 2005; Kahn et al., 2007).”
InfluentialAdherence beliefs among breast cancer patients taking tamoxifen
Grunfeld, E. A., Hunter, M. S., Sikka, P., & Mittal, S. (2005) · Patient Education and Counseling · doi:10.1016/j.pec.2004.10.005 · Cited by 245 · cited 7×
“Most investigators have found that disease-and treatment-related symptoms are associated with nonadherence to endocrine therapy in women with breast cancer (Demissie et al., 2001; Fink et al., 2004; Grunfeld et al., 2005; Kahn et al., 2007; Wickersham et al., 2013).”
InfluentialWu, X.-C., Lund, M. J., Kimmick, G. G., Richardson, L. C., Sabatino, S. A., Chen, V. W., Fleming, S. T., Morris, C. R., Huang, B., Trentham-Dietz, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.8399 · Cited by 190 · cited 2×
“…characteristics, such as age and race, and nonadherence is not clear (Atkins & Fallowfield, 2006; Demissie et al., 2001; Kahn, Schneider, Malin, Adams, & Epstein, 2007; Murthy et al., 2002; Owusu et al., 2008; Sedjo & Devine, 2011; Partridge, Wang, Winer, & Avorn, 2003; Wu et al., 2012).”
BackgroundA review of the factors associated with patient compliance and the taking of prescribed medicines.
Griffith, S. G. (1990) · PubMed Central · Cited by 188
Stanton, A. L., Bernaards, C. A., & Ganz, P. A. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji069 · Cited by 182 · cited 1×
“…treatment-related symptoms were assessed with the Breast Cancer Prevention Trial (BCPT) Symptom Checklist , a self-report measure of the degree to which women are bothered by 43 hormone therapy-and menopausal-related symptoms in the month prior (Ganz et al., 2000; Stanton, Bernaards, & Ganz, 2005).”
Barrera, M., Caples, H., & Tein, J. (2001) · American Journal of Community Psychology · doi:10.1023/a:1010328115110 · Cited by 180
Sedjo, R. L., & Devine, S. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0952-6 · Cited by 169 · cited 5×
“…and who did not receive chemotherapy before endocrine therapy (Fink et al., 2004) were more likely to discontinue therapy; however, women who had breast-conserving surgery (Owusu et al., 2008) and changed endocrine therapy agents (Sedjo & Devine, 2011) were more likely to be nonadherent to therapy.”
InfluentialChemotherapy and Cognitive Defects in Cancer Patients
Silberfarb, P. M. (1983) · Annual Review of Medicine · doi:10.1146/annurev.me.34.020183.000343 · Cited by 140
Patient noncompliance with self-administered chemotherapy
Lebovits, A. H., Strain, J. J., Messe, M. R., Schleifer, S. J., Tanaka, J. S., & Bhardwaj, S. (1990) · Cancer · doi:10.1002/1097-0142(19900101)65:1<17::aid-cncr2820650106>3.0.co;2-i · Cited by 139 · cited 9×
“…was intensified by a greater number of concomitant medications but weakened by greater concerns about bladder control. of better physical function were related to tamoxifen nonpersistence, differing from Lebovits et al. (1990) who found no relationship between physical function and nonpersistence.”
InfluentialQuality of life and psychosocial status in stage D prostate cancer
Cassileth, B. R., Soloway, M. S., Vogelzang, N. J., Chou, J. M., Schellhammer, P. D., Seidmon, E. J., Kennealey, G. T., & members of the Zoladex Prostate Cancer Study Group (1992) · Quality of Life Research · doi:10.1007/bf00434946 · Cited by 135 · cited 1×
“The POMS is sensitive to changes in anxiety levels in patients with cancer (Cassileth et al., 1992).”
BackgroundCognitive and mood disturbance as causes and symptoms of fatigue in cancer patients
Valentine, A. D., & Meyers, C. A. (2001) · Cancer · doi:10.1002/1097-0142(20010915)92:6+<1694::aid-cncr1499>3.0.co;2-s · Cited by 106
Fogel, J., Albert, S. M., Schnabel, F., Ann Ditkoff, B., & Neugut, A. I. (2003) · Psycho-Oncology · doi:10.1002/pon.617 · Cited by 103
Adjuvant Tamoxifen Prescription in Women 65 Years and Older With Primary Breast Cancer
Silliman, R. A., Guadagnoli, E., Rakowski, W., Landrum, M. B., Lash, T. L., Wolf, R., Fink, A., Ganz, P. A., Gurwitz, J., Borbas, C., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.137 · Cited by 92 · cited 2×
“Evidence also suggested that women with breast cancer who hold negative beliefs about the value of endocrine therapy are more likely to discontinue therapy (Lash, Fox, Westrup, Fink, & Silliman, 2006; Silliman et al., 2002) and are at increased risk for nonadherence (Fink, Gurwitz, Rakowski, Guadagnoli, & Silliman, 20…”
The development of endocrine therapy for women with breast cancer
Sainsbury, R. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.07.006 · Cited by 88 · cited 1×
“As a consequence, plasma estrogen levels are significantly reduced (DownsHolmes & Silverman, 2011; Sainsbury, 2013).”
BackgroundDepression screening scale validation in an elderly, community-dwelling population.
Stukenberg, K. W., Dura, J. R., & Kiecolt-Glaser, J. K. (1990) · Psychological Assessment · doi:10.1037//1040-3590.2.2.134 · Cited by 86
Christensen, A. J. (2000) · Psychosomatic Medicine · doi:10.1097/00006842-200005000-00017 · Cited by 78 · cited 1×
“However, according to Christensen’s interactionist framework, the interactive effects of patient factors and illness or treat-ment factors may provide the dominant influence on nonadherence (Christensen, 2000; Christensen, Smith, Turner, & Cundick, 1994).”
Patient adherence and adjustment in renal dialysis: A person x treatment interactive approach
Christensen, A. J., Smith, T. W., Turner, C. W., & Cundick, K. (1994) · Journal of Behavioral Medicine · doi:10.1007/bf01857597 · Cited by 77
Neuropsychological Correlates of Suboptimal Adherence to Metformin
Rosen, M. I., Beauvais, J. E., Rigsby, M. O., Salahi, J. T., Ryan, C. E., & Cramer, J. A. (2003) · Journal of Behavioral Medicine · doi:10.1023/a:1024257027839 · Cited by 74 · cited 2×
“3, May 2014 • Oncology Nursing Forum Physical function was assessed with the 10-item physical function subscale of the SF36® (Ownby, 2006; Rosen et al., 2003).”
Cohen, M. (2002) · Behavioral Medicine · doi:10.1080/08964280209596394 · Cited by 58 · cited 3×
“The Measure of Economic Hardship is a 20-item measure that assesses financial hardship in four different domains: financial strain, inability to make ends meet, not enough money for necessities, as well as economic cutbacks and adjustments.”
What do perceived cognitive problems reflect?
Bender, C. M., Pacella‐LaBarbara, M. L., Sereika, S. M., Brufsky, A., Vogel, V. G., Rastogi, P., Casillo, F. E., Richey, S. M., & Ryan, C. M. (2008) · The Journal of Supportive Oncology · Cited by 52
Self-citationBreast cancer: Overview & updates
Downs-Holmes, C., & Silverman, P. (2011) · The Nurse Practitioner · doi:10.1097/01.npr.0000407602.29522.d7 · Cited by 50
Ownby, R. L. (2006) · PubMed · Cited by 47
Nonadherence in Patients With Breast Cancer Receiving Oral Therapies
Moore, S. (2010) · Clinical Journal of Oncology Nursing · doi:10.1188/10.cjon.41-47 · Cited by 40
Tamoxifen non-compliance: does it matter?
Murthy, V., Bharia, G., & Sarin, R. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(02)00895-1 · Cited by 35 · cited 3×
“…demographic characteristics, such as age and race, and nonadherence is not clear (Atkins & Fallowfield, 2006; Demissie et al., 2001; Kahn, Schneider, Malin, Adams, & Epstein, 2007; Murthy et al., 2002; Owusu et al., 2008; Sedjo & Devine, 2011; Partridge, Wang, Winer, & Avorn, 2003; Wu et al., 2012).”
Diagnostic Efficiency of the Trail Making Test as a Function of Cut-off Score, Diagnosis, and Age
Gordon, N. G. (1978) · Perceptual and Motor Skills · doi:10.2466/pms.1978.47.1.191 · Cited by 15
Wickersham, K. E., Sereika, S. M., & Bender, C. M. (2013) · Nursing Research · doi:10.1097/nnr.0b013e318298fd70 · Cited by 15 · cited 4×
“Studies that examined the influence of patient and illness or treat-ment factors on nonadherence to endocrine therapy in women with breast cancer have produced conflicting results (Chlebowski & Geller, 2006; Owusu et al., 2008; Wickersham et al., 2013).”
InfluentialSelf-citationAdjuvant endocrine therapy for early breast cancer
Andreetta, C., & Smith, I. (2006) · Cancer Letters · doi:10.1016/j.canlet.2006.10.021 · Cited by 9 · cited 1×
“Endocrine therapies substantially improve the disease-free and overall survival of women with early breast cancer (Andreetta & Smith, 2007).”
Research works printed but not linked: 3
- D. McNair, 1992, EdITS manual for the profile of mood states
- H. Nelson, 1981, National adult reading test (NART) manual
- O. Spreen, 1998, A compendium of neuropsychogical test: Administration, norms, and commentary
Cited by
Financial Burdens of Cancer Treatment: A Systematic Review of Risk Factors and Outcomes
Smith, G. L., Lopez-Olivo, M. A., Advani, P. G., Ning, M. S., Geng, Y., Giordano, S. H., & Volk, R. J. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.7305 · Cited by 437
A Systematic Review of Adherence to Oral Antineoplastic Therapies
Greer, J. A., Amoyal, N., Nisotel, L., Fishbein, J. N., MacDonald, J., Stagl, J., Lennes, I., Temel, J. S., Safren, S. A., & Pirl, W. F. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0405 · Cited by 344
Management of Anxiety and Depression in Adult Survivors of Cancer: ASCO Guideline Update
Andersen, B. L., Lacchetti, C., Ashing, K., Berek, J. S., Berman, B. S., Bolte, S., Dizon, D. S., Given, B., Nekhlyudov, L., Pirl, W., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00293 · Cited by 318
Impact of the COVID-19 Pandemic on Patient-Reported Outcomes of Breast Cancer Patients and Survivors
Bargon, C. A., Batenburg, M. C. T., van Stam, L. E., Mink van der Molen, D. R., van Dam, I. E., van der Leij, F., Baas, I. O., Ernst, M. F., Maarse, W., Vermulst, N., et al. (2021) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkaa104 · Cited by 268
Mausbach, B. T., Schwab, R. B., & Irwin, S. A. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3471-7 · Cited by 164
Metadata
- Authors
- Bender, C. M., Gentry, A. L., Brufsky, A. M., Casillo, F. E., Cohen, S. M., Dailey, M. M., Donovan, H. S., Dunbar-Jacob, J., Jankowitz, R. C., Rosenzweig, M. Q., Sherwood, P. R., & Sereika, S. M.
- Affiliations
- UPMC Hillman Cancer Center (US)
- University of Pittsburgh (US)
- ORCID
- Venue
- Oncology Nursing Forum
- Publisher
- Oncology Nursing Society (ONS)
- Published
- 2014-04-25
- Volume
- 41
- Issue
- 3
- Pages
- 274-285
- ISSN
- 0190-535X (ISSN-L)
- 1538-0688
- PMC
- PMC4090095
- OpenAlex
- W1992203573
- Cited by
- 131
- References
- 50
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 7 · 2023: 7 · 2022: 16 · 2021: 15 · 2020: 17 · 2019: 11 · 2018: 12 · 2017: 15 · 2016: 8 · 2015: 8 · 2014: 1
- FWCI
- 10.95
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Oncology nursing forum (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UL1TR000005)
- National Cancer Institute (R01CA107408)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Women's cancer prevention and management
- Keywords
- breast cancer, adjuvant endocrine therapy, medication adherence, non-compliance, negative mood, depression, anxiety, financial hardship, symptom burden, disease stage, medication regimen complexity, predictors of non-adherence
- MeSH terms
- Adolescent, Adult, Affect, Aged, Breast Neoplasms, Depression, Female, Follow-Up Studies, Forecasting, Humans, Middle Aged, Patient Compliance, Pennsylvania, Socioeconomic Factors, Tamoxifen, Time Factors, Comorbidity, Chemotherapy, Adjuvant, Antineoplastic Agents, Hormonal, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.